Foster Dykema Cabot & Partners, LLC Vertex Pharmaceuticals Inc Transaction History
Foster Dykema Cabot & Partners, LLC
- $1.12 Trillion
- Q2 2024
A detailed history of Foster Dykema Cabot & Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Foster Dykema Cabot & Partners, LLC holds 59,975 shares of VRTX stock, worth $28.4 Million. This represents 2.51% of its overall portfolio holdings.
Number of Shares
59,975
Previous 59,725
0.42%
Holding current value
$28.4 Million
Previous $25 Billion
12.6%
% of portfolio
2.51%
Previous 2.33%
Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,719Shares Held
225MCall Options Held
1.19MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$12.6 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.9 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.1 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.54 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.04 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $121B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...